Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 726,700 shares, a drop of 63.5% from the February 13th total of 1,990,000 shares. Based on an average trading volume of 6,590,000 shares, the short-interest ratio is presently 0.1 days. Currently, 4.9% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Azitra stock. Virtu Financial LLC boosted its position in Azitra, Inc. (NYSEAMERICAN:AZTR) by 196.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 63,180 shares of the company’s stock after purchasing an additional 41,866 shares during the period. Virtu Financial LLC owned approximately 0.83% of Azitra worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.16% of the company’s stock.

Azitra Stock Performance

Shares of Azitra stock traded up $0.01 on Friday, reaching $0.36. The company had a trading volume of 221,242 shares, compared to its average volume of 8,642,582. The firm’s 50-day simple moving average is $0.35. Azitra has a 1 year low of $0.23 and a 1 year high of $12.00.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.